Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 362

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 362
---
        3,582 |
| Total Common Stock Equivalents         |     |     |       91,108 |     |     |       55,280 |

F-27

LB Pharmaceuticals Inc Notes to Financial Statements 10. Stock-Based Compensation The Company uses equity-based compensation programs to provide long-term performance incentives for its employees, directors and consultants. These incentives consist primarily of stock options and restricted stock grants. In 2017, the Company’s Board of Directors approved the LB Pharmaceuticals Inc 2017 Stock Incentive Plan (“2017 Plan”). The 2017 Plan authorized the issuance of stock options or restricted stock up to 0.8 million shares of the Company’s common stock. In August 2018, the Company amended the 2017 Plan, reducing the maximum aggregate number of shares that may be issued under the 2017 Plan to 0.6 million. No additional awards will be granted under the 2017 Plan. As of both December 31, 2024 and 2023, there were 0.3 million shares outstanding under the 2017 Plan. In 2018, the Company’s Board of Directors approved the LB Pharmaceuticals Inc 2018 Stock Incentive Plan (“2018 Plan”). The 2018 Plan authorized the issuance of stock options or restricted stock up to 1.1 million shares of the Company’s common stock. No additional awards will be granted under the 2018 Plan. As of both December 31, 2024 and 2023, there were 0.8 million shares outstanding under the 2018 Plan. In August 2023, the Company’s Board of Directors approved the LB Pharmaceuticals Inc 2023 Stock Incentive Plan, as amended (“2023 Plan”). The 2023 Plan authorized the issuance of stock options or restricted stock up to 8.1 million shares of the Company’s common stock. In December 2024, the Company amended the 2023 Plan increasing the maximum aggregate number of shares that may be issued under the 2023 Plan to approximately 13.0 million. The 2023 Plan expires in August 2033. As of December 31, 2024 and 2023, there were 11.7 million and 2.5 million shares outstanding, respectively. As of December 31, 2024, there are 1.3 million shares available for future issuance under the 2023 Plan. Stock Options Stock options vest based on one of the